Reducing glucose damage in pancreatic beta cells
Alleviation of Glucotoxicity in Pancreatic Beta Cells
This study is looking at how high blood sugar can hurt the cells in your pancreas that make insulin, and it's trying to find ways to protect those cells and improve treatments for Type 2 Diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10841505 on NIH RePORTER |
What this research studies
This research investigates how high blood sugar levels harm pancreatic beta cells, which are crucial for insulin production. It aims to understand the molecular mechanisms behind this damage and explore potential therapies to protect these cells from glucose toxicity. By studying both rodent and human models, the research seeks to identify ways to preserve beta cell function and mass, potentially leading to new treatments for Type 2 Diabetes. The approach includes examining specific molecular pathways and testing interventions that could mitigate the harmful effects of sustained high glucose levels.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 2 Diabetes, particularly those experiencing challenges with insulin production.
Not a fit: Patients with Type 1 Diabetes or those whose diabetes is not related to pancreatic beta cell dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that preserve pancreatic beta cell function, improving treatment options for patients with Type 2 Diabetes.
How similar studies have performed: Previous research has shown promise in exploring molecular mechanisms related to beta cell function, indicating that this approach may lead to significant advancements in diabetes treatment.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Scott, Donald K. — Icahn School of Medicine at Mount Sinai
- Study coordinator: Scott, Donald K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.